T he inflammatory bowel diseases (IBDs), comprised of Crohn's disease (CD) and ulcerative colitis (UC), are chronic diseases which severely affect quality of life through debilitating symptoms, reduction in ability to work, social stigma, and limited career choices. 1, 2 Canada has among the highest incidence and prevalence of IBD in the world. 3 The burden that IBD places on individuals, the health care system, and society is staggering and is expected to rise. In Canada, the annual direct medical costs of treating persons with IBD and the costs associated with lost productivity are estimated to be $2.8 billion. 3 The goals of IBD management are to achieve sustained disease remission while avoiding complications of the disease and its treatment. Patients with IBD have increasingly expressed a desire to become engaged in the decision making surrounding their care. The Choosing Wisely Campaign was developed to advance a national dialogue among physicians, patients, and policy makers on avoiding harmful, wasteful, or unnecessary medical tests, treatments, and procedures. With the engagement of over 70 physician specialty societies in the United States and 50 in Canada, Choosing Wisely promotes conversations between providers and patients ("Things Providers and Patients Should Question") that are informed by evidence. Canadian IBD Network for Research and Growth in Quality Improvement (CINERGI), a national consortium of IBD specialists, recognized the need for a Choosing Wisely Campaign for IBD (CWIBD). In partnership with Crohn's and Colitis Canada and the Canadian Association of Gastroenterology, we implemented a modified Delphi consensus process to identify 5 CWIBD items that would promote an open dialogue between patients and their IBD providers regarding potentially harmful or wasteful tests or interventions.
METHODS
Fourteen members of the CINERGI group, who are adult gastroenterologists with specialized training and expertise in IBD at 12 academic centers throughout Canada, were invited to be participants in the consensus working group for CWIBD, and all agreed. The modified Delphi process consisted of 3 rounds of surveys. 4 In the first round, CINERGI members were requested to electronically submit a list of recommendations for CWIBD. Instructions were provided to submit recommendations that began with "Do not." and which advocated against diagnostic tests and interventions in the management of IBD that were overutilized, wasteful, or potentially harmful to patients. In the second round, members rated each of the previously submitted recommendations using a confidential online survey platform (Novi-Survey). Members were asked to rate each candidate statement on a scale from 1 (lowest) to 9 (highest) based on 5 criteria: (1) Frequency/pervasiveness of the test/intervention; (2) Potential to cause harm; (3) Cost-to-benefit ratio; (4) Evidence against the intervention; and (5) Potential to affect clinical practice. The response rate from voting participants was 100%. Based on the mean score, the top 10 statements were identified for the final round of voting that takes place in a face-to-face meeting on November 4, 2016, in Toronto. Members of the working group were given an opportunity to review the list and make an appeal for any additional statements that did not make the top 10 recommendations that they felt should be discussed at the face-to-face meeting.
At the face-to-face meeting, the CINERGI group reviewed each of the 10 candidate statements (Table 1) and tasked with selecting 5 recommendations, a predetermined number that is standard for Choosing Wisely lists. All working group members who voted during the second round participated at the face-to-face meeting. In addition, the Vice President of Research and Patient Programs for Crohn's and Colitis Canada participated in voting. Two patient representatives and 2 academic radiologists also participated in discussions but did not vote. The session was facilitated by an international IBD expert with extensive experience with the modified Delphi process. After a presentation of summary of evidence by an IBD fellow who conducted the literature searches, each recommendation was discussed taking into consideration the frequency of the test or intervention; potential for the test or intervention to cause harm; cost-to-benefit ratio; supporting evidence against the intervention; and the potential impact of the recommendation on clinical practice. During discussions, statements were reworded as necessary to achieve maximum consensus. Members formally rated the recommendations on a scale from 1 (lowest) to 3 (highest) along each of the above dimensions. Members also voted on an independent overall impact rating scale from 1 to 9 ( Fig. 1) (1-3 ¼ low impact, 4-6 ¼ uncertain, and 7-9 ¼ high impact). The group was then presented a ranked list based on the overall score for final review. A final round of voting for the top 5 statements was conducted among all statements with a median rating of 7 or higher.
RESULTS
In the first round of the survey, 30 CWIBD recommendations were submitted electronically after duplicate or similar statements were removed. Twenty-four of these focused on b Don't use intravenous corticosteroids alone for more than 5 days in patients with acute severe ulcerative colitis in the absence of clinical response. Recommendation #6 Don't continue a biologic if the patient has not had a clinical response within 12 weeks of initiating therapy. Recommendation #7 Don't switch to another biologic within the same class when there has been a primary non-response to the first biologic. Recommendation #8 Don't treat isolated, symptomatic fibrostenotic strictures in Crohn's disease with medical therapy. Recommendation #9 Don't restrict oral nutrition in hospitalized IBD patients on bowel rest unless there is concern for bowel obstruction or perforation. Recommendation #10 Don't use oral mesalamine for the treatment Crohn's disease. therapeutic interventions (80%), whereas the remaining 6 addressed diagnostic testing (20%). The second round of online rating yielded 10 statements ( Table 1 ) that would be brought forward to the third face-to-face round of voting. After the third round of voting, Recommendations #1, 2, 3, and 5 were ranked in the top 4, and all achieved mean and median scores above 7, which was in the range of being impactful (Table 2) . Recommendations #4, 9, and 10 had median scores of 7 but mean scores ranging from 6.1 to 6.6. Because these statements were in the borderline range for being impactful, another round of voting using an ordinal scale of first, second, and third choice was initiated to rank these 3 in order of preference. Recommendation #4 yielded the highest preference and was added as the fifth recommendation. The CINERGI group reached consensus to accept the 5-item CWIBD list, which is individually discussed below. Recommendation #1: Don't use steroids (e.g., prednisone) for maintenance therapy in inflammatory bowel disease.
Summary of Recommendation: Although systemic corticosteroids (e.g., prednisone) are effective in inducing symptomatic remission in IBD, they are ineffective as maintenance therapy and are associated with both short-and long-term serious adverse effects. Consequently, if initial steroid taper is unsuccessful, health providers should consider adding a steroid-sparing agent that has proven efficacy and safety as maintenance therapy in patients with IBD.
Although conventional corticosteroids have proven efficacy as induction agents, they have not proven effective as maintenance therapy in CD. A comprehensive Cochrane meta-analysis showed that maintenance therapy with corticosteroids did not reduce rates of disease relapse at 24 months. 5 Glucocorticoids rapidly achieve disease remission and are occasionally used as a bridge to long-term immunomodulators such as azathioprine. 6 Moreover, long-term treatment with systemic steroids can cause serious adverse effects, including suppression of the hypothalamic pituitary adrenal axis, diabetes mellitus, osteoporosis, avascular necrosis, cataracts, truncal obesity, and hypertension. 7, 8 Systemic steroids have also been associated with risk of serious infections and higher mortality in IBD. 9, 10 Budesonide, a second-generation glucocorticoid preparation with proven efficacy in the treatment of IBD and a more favorable side-effect profile than prednisone, has also been shown to achieve remission in CD. However, it did not prove effective as 12 Although this formulation is better tolerated than other conventional glucocorticoids, there are still gastrointestinal and endocrine-related adverse effects. 13 Furthermore, prolonged use of budesonide may also lead to loss of bone mass, although to a lesser extent than that seen with prednisolone. 14, 15 In population-based cohorts, 12% to 38% of patients with IBD required a prolonged course of systemic steroids. [16] [17] [18] Steroid dependence may be defined as one of the following: inability to taper off of steroids within 3 months without recurrence of symptoms, symptomatic relapse occurring within 3 months of stopping corticosteroids, or requirement of 2 or more courses of steroids within 12 months. 19 Patients with IBD who are steroid dependent should be offered steroid-sparing therapy (e.g., immunomodulators, biologics) that is effective for maintenance of remission. [19] [20] [21] Recommendation #2: Don't use opioids long-term to manage abdominal pain in inflammatory bowel disease.
Summary of Recommendation: Although opioids may be used to manage abdominal pain in select acute settings in patients with IBD, their prolonged use may mask the symptoms of active IBD or its complications (e.g., bowel perforation or megacolon). Chronic opioid use has been proven ineffective for nonmalignancyassociated chronic pain and is associated with excess mortality. Moreover, because of their significant addictive potential, their long-term use for managing IBD-related abdominal pain should be avoided, especially in the context of the opioid crisis in North America.
Pain, both abdominal and extraintestinal, is major contributor to poor quality of life for patients with IBD. The onset or progression of pain should be investigated for the presence of inflammatory activity using endoscopy, biomarkers (such as fecal calprotectin), and imaging studies (e.g., magnetic resonance imaging) for small bowel or fistulizing disease when appropriate.
Approximately 20% to 30% of patients will continue to report pain, despite confirmation of mucosal healing and disease remission. 22, 23 This discordance may be due to coexistent functional bowel disorders such as irritable bowel syndrome (IBS), which affects 20% of patients with IBD. [24] [25] [26] [27] Functional gastrointestinal disorders, anxiety, depression, female sex, and a history of narcotic abuse are all associated with an increased likelihood of opioid use among patients with IBD. 24, [28] [29] [30] [31] The proportion of patients with IBD taking narcotics is increasing, with estimates in the United States ranging from 5% to 13%. 30, 32, 33 A retrospective analysis of hospitalized patients with IBD at a tertiary IBD center showed that 70% were prescribed opioids during their inpatient stay. Predictors of inpatient opioid use was CD diagnosis, duration of inpatient stay, psychiatric comorbidities, smoking, history of IBD surgery, and previous outpatient opioid use. Interestingly, all patients with coexisting IBD-IBS were prescribed opioids during their hospitalization. Over half of those patients received a prescription for narcotics on discharge. 32 Predictors of being discharged with an opioid prescription included previous opioid use, surgery, and perianal disease.
Although opioids may have a role in controlling diarrhea in select patients with chronic IBD, particularly in the context of resection of the small bowel and/or ileocecal valve, their chronic use for pain control is fraught with complications and long-term difficulties including dependence. Adverse effects of opiate use include nausea, mood alterations, sedation, and constipation, which may be progressive and particularly dangerous in patients with severe colitis at risk of toxic megacolon. 34, 35 Moreover, use of opiates in IBD may lead to a vicious cycle of increased narcotic use to manage the side effects of these medications, and potentially lead to difficulty in distinguishing symptoms associated with active IBD from adverse drug effects. Opioid-related complications such as narcotic bowel syndrome, dependence, and intestinal pseudo-obstruction may occur, especially after long-term use in CD. 36 Chronic use of opioids exceeding 50 mg of morphine equivalents daily is also associated with a 2-to 3-fold increased risk of mortality in noncancer patients and more specifically in patients with IBD. 10, 37, 38 In patients with CD, opioids have also been associated with increased risk of serious infections. 10 The approach to pain management in IBD should first address inflammatory activity. An analysis of patients with IBD requiring opioids showed that more than half were weaned from these drugs successfully through the optimization of IBD medical therapy; medication adherence was predictive of successful weaning. 28 Where there are persistent symptoms of pain despite optimal medical therapy, use of opioids may be required. However, there are sparse data supporting the use or benefit of these drugs in the long-term management of pain and minimal evidence of positive impact on quality of life or in restoration of function previously limited by pain. 39, 40 When unavoidable, long-term opioids should be prescribed by pain specialists ideally with patient monitoring and access to psychological supports. Initiating an opioid contract with patients on the appropriate use of opioids for pain management may also be helpful. 41 Recommendation #3: Don't unnecessarily prolong the course of intravenous corticosteroids in patients with acute severe ulcerative colitis (UC) in the absence of clinical response.
Summary of Recommendation: Non-response to intravenous corticosteroids for acute severe UC can be predicted after the first 72 hours of treatment. However, about a third of nonresponders receive systemic steroid monotherapy beyond 7 days. This prolonged use of ineffective systemic steroids may unnecessarily lengthen hospitalization days and increase risk of postoperative complications in those who eventually require colectomy.
Intravenous corticosteroids are the cornerstone of management of acute severe UC, and many early treatment decisions are dependent on response to steroids. Intravenous corticosteroids are usually administered in patients hospitalized with acute severe UC. Meta-analyses of cohort and controlled trials have not shown any benefit of doses, methylprednisolone, higher than 60 mg per day (or equivalent). Based on a systematic review, two-thirds of hospitalized patients with UC have a clinical response to intravenous corticosteroids. 42 Clinical response should be assessed within 72 hours of initiation of intravenous corticosteroids based on stool frequency, rectal bleeding, abdominal pain, and general well-being, as well as hematological and biochemical parameters. 43 In one study, the presence of 8 or more stools per day, or 3 to 8 stools per day combined with a C-reactive protein .45 mg/L by the third day of intravenous corticosteroid treatment were indicators of nonresponse and predicted colectomy in 85% of patients. 44 Similarly, another study identified persistent stool frequency .6 per day with the presence of blood as a predictor of steroid refractoriness. 45 Medical rescue therapy with an anti-tumor necrosis factor agent or cyclosporine should be considered, if there is no clinical response by 72 hours with the goal of starting rescue therapy within 5 days of initiating steroids. 43 The continued administration of intravenous steroids without considering alternate therapies may ultimately increase morbidity and complications associated with acute severe colitis. Patients whom are referred for colectomy after failing prolonged (over 8 d) preoperative medical therapy had an increased risk of major postoperative complications. 46, 47 In addition, the risk of short-term postoperative infectious complications in persons with UC is associated with preoperative exposure to intravenous steroids but not infliximab. 48 Recommendation #4: Don't initiate or escalate long-term medical therapies for the treatment of inflammatory bowel disease (IBD) based only on symptoms.
Summary of Recommendation: Clinical symptoms often prompt initiation or escalation of medical treatments for inflammatory bowel disease (IBD). However, functional bowel disorders (e.g. irritable bowel syndrome) coexist in 20% of IBD patients and can mimic symptoms of the latter. Clinical symptoms, in fact, do not correlate well with IBD disease activity. Consequently, relying on only clinical symptoms without confirming active disease may commit patients to long-term treatments that have potentially significant adverse effects and resource implications.
Effective management of IBD should address symptoms and prevent long-term complications of disease. However, treatment of gastrointestinal or extraintestinal symptoms with immunosuppressive drugs in the absence of objective evidence of disease activity exposes patients with IBD to potential treatment toxicities without providing benefit. On the other hand, not treating patients who are in clinical remission may miss many patients who have asymptomatic disease activity, increasing their risk of long-term complications. 49 Symptoms tend to correlate poorly with endoscopic disease activity in IBD, particularly in CD. 50, 51 A number of functional gastrointestinal disorders, particularly IBS, may coexist with IBD and may be the underlying cause of symptoms in many patients. A fifth of patients with IBD may have superimposed IBS. 27 In such individuals, intensifying medical therapy for an indefinite length of time without objective evidence of inflammatory activity may lead to unnecessary drug-related adverse events and drug-related costs. Moreover, treating symptoms alone has not been shown to alter disease course in IBD.
Mucosal healing, however, correlates with improved IBD patient outcomes, including corticosteroid-free survival, fewer hospitalizations, and surgery. [52] [53] [54] [55] [56] [57] [58] [59] However, the absence of clinical symptoms correlates poorly with mucosal healing. In one retrospective study, over two-thirds of patients with UC and CD have mucosal inflammation despite reporting clinical remission. 60 In the ACCENT 1 trial, 40% of patients with CD in clinical remission as defined by Crohn's Disease Activity Index (CDAI) score did not achieve mucosal healing. 61 Thus, in asymptomatic patients, decisions to de-escalate or discontinue maintenance therapy should not be made without objectively documenting the absence of disease.
Because of the frequent discrepancy between symptoms and endoscopic disease activity, there has been a paradigm shift toward targeting mucosal healing as an objective endpoint rather than symptomatic remission. These trends are reflected in clinical practice guidelines by for CD and UC by the European Crohn's and Colitis Organisation, the International Organization for the Study of Inflammatory Bowel Disease (IOIBD), and the Canadian Association of Gastroenterology. 19, 52, 62 In the setting of postoperative CD, endoscopic recurrence precedes and predicts clinical recurrence. Accordingly, clinical guidelines by the American Gastroenterological Association recommend endoscopic surveillance after surgery for CD to guide medical management. 63 Although endoscopic evaluation remains a cornerstone for managing IBD, biomarkers (e.g., fecal calprotectin) and imaging are alternative modalities that enable objective assessment of disease activity. 64, 65 Recommendation #5: Don't use abdominal computed tomography (CT) scan to assess inflammatory bowel disease (IBD) in the acute setting unless there is suspicion of a complication (obstruction, perforation, and abscess) or a non-IBD etiology for abdominal symptoms.
Summary of Recommendation: Abdominal CT is effective for the time-sensitive diagnosis of IBD complications, such as obstruction, perforation, or non IBD-related causes of abdominal pain when these are suspected. The effective ionizing radiation dose from a single conventional abdominal CT (10-20 mSv) is within acceptable safety limits (,50 mSv). However, minimizing inappropriate utilization of CT is a priority because repeated exposure to ionizing radiation over a lifetime, particularly among younger patients with IBD, may potentially increase the risk of malignancy. In the acute setting (e.g., emergency department), abdominal CT should only be used when there is suspicion of a complication of IBD and should not be used for the assessment of disease activity.
Abdominal computed tomography (CT) has an important role in the rapid assessment of complications from IBD, especially in patients with symptoms of IBD presenting to emergency departments. However, abdominal CT should not be indiscriminately ordered on all patients with IBD presenting with an acute exacerbation of their disease. Abdominal CT is effective in confirming suspected obstruction, perforation, abscess, or other causes of abdominal pain not directly related to IBD (e.g., nephrolithiasis). 66 Patients should only be referred if there is a reasonable suspicion for one of these indications which may require surgical or other intervention. The yield for significant findings including obstruction, abscess, and intestinal perforation ranges from 17% to 34%. [67] [68] [69] Based on retrospective studies, predictors of significant CT findings requiring specific interventions among patients with IBD include but are not limited to history of intestinal obstruction, leukocytosis, history of intra-abdominal abscess, and clinical evidence of sepsis. [69] [70] [71] CT scans performed on patients with UC presenting in the emergency department tend to be lower yield with only 2% revealing an IBD-related complication. 72 The likelihood of a clinically significant CT finding is 5-fold lower if a negative CT was performed within a month prior. 73 The European Crohn's and Colitis Organisation (ECCO) and European Society of Gastrointestinal and Abdominal Radiology (ESGAR) combined guidelines advise that in the evaluation of acute abdominal pain, CT should only be used in patients with IBD with negative first-line investigations of abdominal plain xray or ultrasound, or with suspected intestinal perforation. 74 In the United States, emergency departments saw a 2-fold rise in the use of CT imaging for abdominal pain between 2001 and 2005, and this trend was similar among patients with CD. 67, 75 Patients with IBD may be particularly susceptible to increased cumulative doses of radiation due to the chronicity of their disease and their high rates of emergency department use. A metaanalysis reported that 11.1% patients with CD and 2% with UC have received potentially harmful cumulative doses of radiation over the course of their illness. 76 A retrospective study showed that patients with CD were more likely than those with UC to have had CT (34% versus 20%) and higher cumulative ionizing radiation exposure (14.3 versus 5.8 mSv) within a 5-year followup period. In this study, three-quarters of ionizing radiation exposure was due to CT imaging, and 7% of patients with CD received high levels of radiation defined as .50 mSv per 5 years. 77 It should be emphasized that a single standard abdominal and pelvic CT imparts 10 to 20 mSv which is a safe level of radiation exposure (,50 mSv). 78 Recent technical developments have even allowed abdominal CT to be routinely performed with ,3 mSv (low-dose CT enterography). However, because patients with IBD are often diagnosed at a young age, it is the cumulative exposure over a lifetime that is concerning. The potential for overuse of CT may be exacerbated in an emergency department setting where providers may not have access to a patient's history of prior CT imaging.
SUMMARY
Through a structured consensus process, we have made recommendations to avoid 5 diagnostic and therapeutic interventions that are unnecessary, overutilized, or perhaps even harmful. We should note that the expert panel comprised adult gastroenterologists, and the literature search focused on data from adult IBD populations. Consequently, these recommendations target patients with IBD who are 18 years and older and their respective IBD providers. We acknowledge that a limitation of this consensus-driven initiative was that the body of evidence was often drawn from observational studies. Specifically, our fifth recommendation against the use of CT for assessment of IBD activity was driven by single-center retrospective studies. Future prospective studies could strengthen that recommendation through the development of more precise prediction models of which patients with IBD would benefit from CT. Despite these limitations, we hope these Choosing Wisely recommendations will increase awareness and promote conversations between physicians and patients on the judicious use of these diagnostic tests and treatments.
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